title: [Risk factors for duration of urinary incontinence after radical prostatectomy].
abstract: OBJECTIVE
  In this study, we examined risk factors for duration of incontinence after radical prostatectomy at our hospital.
  
  
  METHODS
  From April 1988 to March 2000, 45 patients with prostate cancer underwent retropubic radical prostatectomy at our hospital. Thirty-eight of 45 patients could be followed up. The patients' age, height, weight, body mass index (BMI), preoperative prostatic specific antigen level, clinical stage, nerve-sparing surgery or none, operation time, bleeding volume, resected prostate weight, cancer positive or negative at surgical margins, postoperative stage, radiation therapy or none, anti-androgen therapy or none, duration of postoperative incontinence, and follow-up period were examined.
  
  
  RESULTS
  All patients had postoperative stress incontinence, and no one had urge incontinence. Medians of duration of postoperative incontinence and follow-up period were 5.5 and 12 months, respectively. When the patients were divided into 2 groups by the value of each parameter, postoperative anti-androgen therapy (chi 2 test, p = 0.0429) and high BMI (> or = 25.0 kg/m2, p = 0.0206) were related to the long duration (> or = 5.5 months) of postoperative incontinence.
  
  
  CONCLUSIONS
  These results suggest that common factors are involved in the etiology of prolonged incontinence after radical prostatectomy and genuine stress incontinence in women. Therefore, both body weight control and pelvic floor muscle exercise might be also important for the treatment of incontinence after radical prostatectomy.
authors.affiliation: Department of Urology, Faculty of Medicine, University of the Ryukyus.
authors.forename: Kimio
authors.initials: K
authors.lastname: Sugaya
authors.forename: Masami
authors.initials: M
authors.lastname: Oda
authors.forename: Saori
authors.initials: S
authors.lastname: Nishijima
authors.forename: Shuichi
authors.initials: S
authors.lastname: Shimabukuro
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ashimine
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Sunabe
authors.forename: Hiroichi
authors.initials: H
authors.lastname: Shimabukuro
authors.forename: Masato
authors.initials: M
authors.lastname: Goya
authors.forename: Haruo
authors.initials: H
authors.lastname: Kagawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yonoh
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shiroma
authors.forename: Tomonori
authors.initials: T
authors.lastname: Miyazato
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Koyama
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hatano
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Owan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D015992:Body Mass Index; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery; D012307:Risk Factors; D014550:Urinary Incontinence, Stress / Q000209:etiology*
chemical_list: D000726:Androgen Antagonists